Free Trial
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$25.68 -1.20 (-4.48%)
Closing price 05/7/2026 03:59 PM Eastern
Extended Trading
$25.86 +0.19 (+0.73%)
As of 06:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Advanced

Key Stats

Today's Range
$25.35
$27.12
50-Day Range
$14.51
$31.01
52-Week Range
$13.74
$70.43
Volume
18.55 million shs
Average Volume
32.57 million shs
Market Capitalization
$5.85 billion
P/E Ratio
50.35
Dividend Yield
N/A
Price Target
$31.86
Consensus Rating
Hold

Company Overview

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 84% of companies evaluated by MarketBeat, and ranked 87th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 4 buy ratings, 12 hold ratings, and 1 sell rating.

  • Upside Potential

    Hims & Hers Health has a consensus price target of $31.86, representing about 24.1% upside from its current price of $25.68.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 26.42% in the coming year, from $0.53 to $0.67 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is 50.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.14.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is 50.35, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.45.

  • Price to Earnings Growth Ratio

    Hims & Hers Health has a PEG Ratio of 3.67. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 10.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    35.47% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 3.01, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently decreased by 2.22%, indicating that investor sentiment is improving.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Hims & Hers Health this week, compared to 13 articles on an average week.
  • Search Interest

    Only 189 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • MarketBeat Follows

    31 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 19% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,285,706.00 in company stock.

  • Percentage Held by Insiders

    13.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Stock News Headlines

Lilly-branded insulin pen and vial on a desk beside a digital scale and measuring tape, representing diabetes treatment.
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims (HIMS)
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
Hims logo overlaid on an apple, measuring tape, and assorted supplement capsules on a pink background.
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means
Amazon is stepping into the GLP-1 arena, with the consumer giant positioning itself as a competitor to Hims & Hers Health. Hims may have a problem on its hands.
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $32.45 at the start of the year. Since then, HIMS stock has decreased by 20.9% and is now trading at $25.6770.

Hims & Hers Health, Inc. (NYSE:HIMS) announced its quarterly earnings data on Monday, February, 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health's revenue for the quarter was up 28.4% on a year-over-year basis.
Read the conference call transcript
.

Hims & Hers Health's board authorized a share repurchase program on Monday, November 17th 2025, which allows the company to repurchase $250,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 3% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued.

Top institutional shareholders of Hims & Hers Health include State of Michigan Retirement System (1.03%), Bank of New York Mellon Corp (0.59%), Principal Financial Group Inc. (0.56%) and Dimensional Fund Advisors LP (0.29%). Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Christiane Pendarvis, Irene Becklund, Irene Becklund, Deborah M Autor, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
2/23/2026
Today
5/08/2026
Next Earnings (Confirmed)
5/11/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Healthcare
Current Symbol
NYSE:HIMS
CIK
1773751
Fax
N/A
Employees
2,442
Year Founded
2017

Price Target and Rating

High Price Target
$68.00
Low Price Target
$18.00
Potential Upside/Downside
+24.1%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.51
Trailing P/E Ratio
50.35
Forward P/E Ratio
48.45
P/E Growth
3.67
Net Income
$128.37 million
Net Margins
5.47%
Pretax Margin
5.28%
Return on Equity
22.48%
Return on Assets
7.02%

Debt

Debt-to-Equity Ratio
1.80
Current Ratio
1.90
Quick Ratio
1.70

Sales & Book Value

Annual Sales
$2.35 billion
Price / Sales
2.49
Cash Flow
$0.80 per share
Price / Cash Flow
32.12
Book Value
$2.38 per share
Price / Book
10.79

Miscellaneous

Outstanding Shares
227,940,000
Free Float
196,689,000
Market Cap
$5.85 billion
Optionable
Optionable
Beta
2.43

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NYSE:HIMS) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners